Antiplatelet is superior to anticoagulant treatment after coronary stenting: Fewer coronary and other events within 30 days after stenting

Stefanos Foussas, Constantine Fakiolas, Dimitrios Alexopoulos, Evagellos Pissimisis, Christodoulos Stefanadis, Alexander Stefanidis, Christoforos Olympios, Michael Zairis, Vasilis Voudris, Gregory Pavlides, Stavros Hatzimiltiadis, Spyros Vitakis, Dimitriïs Sionis, George Louridas, Emmanouel Vavouranakis, Dennis Cokkinos, Antonis Vrahatis, Pavlos Toutouzas

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Stent prosthesis is a high efficacious method with low complication rates. However, the ideal adjunctive therapy following stent implantation remains controversial. The authors compared the effectiveness and complication rates of aspirin-ticlopidine antiplatelet therapy vs anticoagulant therapy with acenocoumarol within 30 days following stent prosthesis. They prospectively studied 404 patients following stent prosthesis while randomly receiving anticoagulant (Group A: 201 patients) vs antiplatelet treatment (Group B: 203 patients). Groups A and B were similar in demographic data (age, gender) stent location, clinical presentation, indication of stenting, and type of implanted stent. Chi-square test, t test, and Wilcoxon test for two samples were used for statistical analysis of the results. Stent implantation was attempted in 434 cases. This was successful in 70/85 (82%) of the bailout, 122/135 (90%) of the suboptimal, and 212/214 (99%) of the elective cases. In 201 patients anticoagulant treatment with acenocoumarol was administered for 4 weeks (group A) while 203 received antiplatelet treatment with ticlopidine (group B). The need for reintervention was less and total cardiac events were fewer in group B than in group A: three (1.5%) and nine (4.4%) vs 18 (9%) and 29 (14.4%) p < 0.0008 and p < 0.006 respectively. Hemorrhagic complications and total noncardiac events were fewer in group B than in group A: six (3%) and six (3%) vs 18 (9%) and 19 (9.5%) p < 0.01 and p < 0.007 respectively. The length of hospital stay was shorter in group B than in A, p < 0.0001. In conclusion, in this study of intracoronary stenting the authors had a high success rate in 434 attempted cases. Antiplatelet therapy was accompanied by fewer cardiac and noncardiac 1 month events when compared with anticoagulant therapy, supporting its role as the adjunctive treatment of choice post-stenting for the time being.

Original languageEnglish (US)
Pages (from-to)289-294
Number of pages6
JournalAngiology
Volume51
Issue number4
StatePublished - Apr 1 2000

Fingerprint

Anticoagulants
Stents
Acenocoumarol
Prostheses and Implants
Ticlopidine
Therapeutics
Length of Stay
Chi-Square Distribution
Aspirin
Demography

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Foussas, S., Fakiolas, C., Alexopoulos, D., Pissimisis, E., Stefanadis, C., Stefanidis, A., ... Toutouzas, P. (2000). Antiplatelet is superior to anticoagulant treatment after coronary stenting: Fewer coronary and other events within 30 days after stenting. Angiology, 51(4), 289-294.

Antiplatelet is superior to anticoagulant treatment after coronary stenting : Fewer coronary and other events within 30 days after stenting. / Foussas, Stefanos; Fakiolas, Constantine; Alexopoulos, Dimitrios; Pissimisis, Evagellos; Stefanadis, Christodoulos; Stefanidis, Alexander; Olympios, Christoforos; Zairis, Michael; Voudris, Vasilis; Pavlides, Gregory; Hatzimiltiadis, Stavros; Vitakis, Spyros; Sionis, Dimitriïs; Louridas, George; Vavouranakis, Emmanouel; Cokkinos, Dennis; Vrahatis, Antonis; Toutouzas, Pavlos.

In: Angiology, Vol. 51, No. 4, 01.04.2000, p. 289-294.

Research output: Contribution to journalArticle

Foussas, S, Fakiolas, C, Alexopoulos, D, Pissimisis, E, Stefanadis, C, Stefanidis, A, Olympios, C, Zairis, M, Voudris, V, Pavlides, G, Hatzimiltiadis, S, Vitakis, S, Sionis, D, Louridas, G, Vavouranakis, E, Cokkinos, D, Vrahatis, A & Toutouzas, P 2000, 'Antiplatelet is superior to anticoagulant treatment after coronary stenting: Fewer coronary and other events within 30 days after stenting', Angiology, vol. 51, no. 4, pp. 289-294.
Foussas S, Fakiolas C, Alexopoulos D, Pissimisis E, Stefanadis C, Stefanidis A et al. Antiplatelet is superior to anticoagulant treatment after coronary stenting: Fewer coronary and other events within 30 days after stenting. Angiology. 2000 Apr 1;51(4):289-294.
Foussas, Stefanos ; Fakiolas, Constantine ; Alexopoulos, Dimitrios ; Pissimisis, Evagellos ; Stefanadis, Christodoulos ; Stefanidis, Alexander ; Olympios, Christoforos ; Zairis, Michael ; Voudris, Vasilis ; Pavlides, Gregory ; Hatzimiltiadis, Stavros ; Vitakis, Spyros ; Sionis, Dimitriïs ; Louridas, George ; Vavouranakis, Emmanouel ; Cokkinos, Dennis ; Vrahatis, Antonis ; Toutouzas, Pavlos. / Antiplatelet is superior to anticoagulant treatment after coronary stenting : Fewer coronary and other events within 30 days after stenting. In: Angiology. 2000 ; Vol. 51, No. 4. pp. 289-294.
@article{e6eb9f2ac3454b7ca1a065a8403c276b,
title = "Antiplatelet is superior to anticoagulant treatment after coronary stenting: Fewer coronary and other events within 30 days after stenting",
abstract = "Stent prosthesis is a high efficacious method with low complication rates. However, the ideal adjunctive therapy following stent implantation remains controversial. The authors compared the effectiveness and complication rates of aspirin-ticlopidine antiplatelet therapy vs anticoagulant therapy with acenocoumarol within 30 days following stent prosthesis. They prospectively studied 404 patients following stent prosthesis while randomly receiving anticoagulant (Group A: 201 patients) vs antiplatelet treatment (Group B: 203 patients). Groups A and B were similar in demographic data (age, gender) stent location, clinical presentation, indication of stenting, and type of implanted stent. Chi-square test, t test, and Wilcoxon test for two samples were used for statistical analysis of the results. Stent implantation was attempted in 434 cases. This was successful in 70/85 (82{\%}) of the bailout, 122/135 (90{\%}) of the suboptimal, and 212/214 (99{\%}) of the elective cases. In 201 patients anticoagulant treatment with acenocoumarol was administered for 4 weeks (group A) while 203 received antiplatelet treatment with ticlopidine (group B). The need for reintervention was less and total cardiac events were fewer in group B than in group A: three (1.5{\%}) and nine (4.4{\%}) vs 18 (9{\%}) and 29 (14.4{\%}) p < 0.0008 and p < 0.006 respectively. Hemorrhagic complications and total noncardiac events were fewer in group B than in group A: six (3{\%}) and six (3{\%}) vs 18 (9{\%}) and 19 (9.5{\%}) p < 0.01 and p < 0.007 respectively. The length of hospital stay was shorter in group B than in A, p < 0.0001. In conclusion, in this study of intracoronary stenting the authors had a high success rate in 434 attempted cases. Antiplatelet therapy was accompanied by fewer cardiac and noncardiac 1 month events when compared with anticoagulant therapy, supporting its role as the adjunctive treatment of choice post-stenting for the time being.",
author = "Stefanos Foussas and Constantine Fakiolas and Dimitrios Alexopoulos and Evagellos Pissimisis and Christodoulos Stefanadis and Alexander Stefanidis and Christoforos Olympios and Michael Zairis and Vasilis Voudris and Gregory Pavlides and Stavros Hatzimiltiadis and Spyros Vitakis and Dimitri{\"i}s Sionis and George Louridas and Emmanouel Vavouranakis and Dennis Cokkinos and Antonis Vrahatis and Pavlos Toutouzas",
year = "2000",
month = "4",
day = "1",
language = "English (US)",
volume = "51",
pages = "289--294",
journal = "Angiology",
issn = "0003-3197",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Antiplatelet is superior to anticoagulant treatment after coronary stenting

T2 - Fewer coronary and other events within 30 days after stenting

AU - Foussas, Stefanos

AU - Fakiolas, Constantine

AU - Alexopoulos, Dimitrios

AU - Pissimisis, Evagellos

AU - Stefanadis, Christodoulos

AU - Stefanidis, Alexander

AU - Olympios, Christoforos

AU - Zairis, Michael

AU - Voudris, Vasilis

AU - Pavlides, Gregory

AU - Hatzimiltiadis, Stavros

AU - Vitakis, Spyros

AU - Sionis, Dimitriïs

AU - Louridas, George

AU - Vavouranakis, Emmanouel

AU - Cokkinos, Dennis

AU - Vrahatis, Antonis

AU - Toutouzas, Pavlos

PY - 2000/4/1

Y1 - 2000/4/1

N2 - Stent prosthesis is a high efficacious method with low complication rates. However, the ideal adjunctive therapy following stent implantation remains controversial. The authors compared the effectiveness and complication rates of aspirin-ticlopidine antiplatelet therapy vs anticoagulant therapy with acenocoumarol within 30 days following stent prosthesis. They prospectively studied 404 patients following stent prosthesis while randomly receiving anticoagulant (Group A: 201 patients) vs antiplatelet treatment (Group B: 203 patients). Groups A and B were similar in demographic data (age, gender) stent location, clinical presentation, indication of stenting, and type of implanted stent. Chi-square test, t test, and Wilcoxon test for two samples were used for statistical analysis of the results. Stent implantation was attempted in 434 cases. This was successful in 70/85 (82%) of the bailout, 122/135 (90%) of the suboptimal, and 212/214 (99%) of the elective cases. In 201 patients anticoagulant treatment with acenocoumarol was administered for 4 weeks (group A) while 203 received antiplatelet treatment with ticlopidine (group B). The need for reintervention was less and total cardiac events were fewer in group B than in group A: three (1.5%) and nine (4.4%) vs 18 (9%) and 29 (14.4%) p < 0.0008 and p < 0.006 respectively. Hemorrhagic complications and total noncardiac events were fewer in group B than in group A: six (3%) and six (3%) vs 18 (9%) and 19 (9.5%) p < 0.01 and p < 0.007 respectively. The length of hospital stay was shorter in group B than in A, p < 0.0001. In conclusion, in this study of intracoronary stenting the authors had a high success rate in 434 attempted cases. Antiplatelet therapy was accompanied by fewer cardiac and noncardiac 1 month events when compared with anticoagulant therapy, supporting its role as the adjunctive treatment of choice post-stenting for the time being.

AB - Stent prosthesis is a high efficacious method with low complication rates. However, the ideal adjunctive therapy following stent implantation remains controversial. The authors compared the effectiveness and complication rates of aspirin-ticlopidine antiplatelet therapy vs anticoagulant therapy with acenocoumarol within 30 days following stent prosthesis. They prospectively studied 404 patients following stent prosthesis while randomly receiving anticoagulant (Group A: 201 patients) vs antiplatelet treatment (Group B: 203 patients). Groups A and B were similar in demographic data (age, gender) stent location, clinical presentation, indication of stenting, and type of implanted stent. Chi-square test, t test, and Wilcoxon test for two samples were used for statistical analysis of the results. Stent implantation was attempted in 434 cases. This was successful in 70/85 (82%) of the bailout, 122/135 (90%) of the suboptimal, and 212/214 (99%) of the elective cases. In 201 patients anticoagulant treatment with acenocoumarol was administered for 4 weeks (group A) while 203 received antiplatelet treatment with ticlopidine (group B). The need for reintervention was less and total cardiac events were fewer in group B than in group A: three (1.5%) and nine (4.4%) vs 18 (9%) and 29 (14.4%) p < 0.0008 and p < 0.006 respectively. Hemorrhagic complications and total noncardiac events were fewer in group B than in group A: six (3%) and six (3%) vs 18 (9%) and 19 (9.5%) p < 0.01 and p < 0.007 respectively. The length of hospital stay was shorter in group B than in A, p < 0.0001. In conclusion, in this study of intracoronary stenting the authors had a high success rate in 434 attempted cases. Antiplatelet therapy was accompanied by fewer cardiac and noncardiac 1 month events when compared with anticoagulant therapy, supporting its role as the adjunctive treatment of choice post-stenting for the time being.

UR - http://www.scopus.com/inward/record.url?scp=0342803580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342803580&partnerID=8YFLogxK

M3 - Article

C2 - 10778998

AN - SCOPUS:0342803580

VL - 51

SP - 289

EP - 294

JO - Angiology

JF - Angiology

SN - 0003-3197

IS - 4

ER -